Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Drops By 14.4%

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 40,400 shares, a drop of 14.4% from the September 30th total of 47,200 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is presently 1.1 days.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC bought a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,040 shares of the company's stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a report on Monday, October 7th.

Entera Bio Price Performance

Shares of Entera Bio stock traded up $0.03 on Tuesday, hitting $1.89. The company had a trading volume of 5,456 shares, compared to its average volume of 120,981. Entera Bio has a 52 week low of $0.52 and a 52 week high of $3.35. The company has a market cap of $67.63 million, a PE ratio of -6.75 and a beta of 1.57. The business has a 50-day simple moving average of $1.85 and a 200-day simple moving average of $1.95.

Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.06). The firm had revenue of $0.06 million for the quarter. On average, equities research analysts predict that Entera Bio will post -0.23 earnings per share for the current fiscal year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.